Advances in the treatment of Hodgkin's lymphoma (Review)
- Authors:
- Yuxuan Che
- Xiaolei Ding
- Liye Xu
- Jian Zhao
- Xian Zhang
- Na Li
- Xiuhua Sun
-
Affiliations: Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116021, P.R. China - Published online on: April 4, 2023 https://doi.org/10.3892/ijo.2023.5509
- Article Number: 61
-
Copyright: © Che et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Hodgkin: On some morbid appearances of the absorbent glands and spleen. Med Chir Trans. 17:68–114. 1832. | |
|
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Johnson P, Federico M, Kirkwood A, Fossa A, Berkahn L, Carella A, d'Amore F, Enblad G, Franceschetto A, Fulham M, et al: Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 374:2419–2429. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, et al: ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 365:203–212. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, et al: Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 372:1598–1607. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ, Petit J, López A, Lahuerta JJ, Carreras E, et al: Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol. 16:625–633. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A, Arora M, Ramsay NK, Orchard PJ, MacMillan ML, et al: Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant. 12:1065–1072. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Sirohi B, Cunningham D, Powles R, Murphy F, Arkenau T, Norman A, Oates J, Wotherspoon A and Horwich A: Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol. 19:1312–1319. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Smith SD, Moskowitz CH, Dean R, Pohlman B, Sobecks R, Copelan E, Andresen S, Bolwell B, Maragulia JC, Vanak JM, et al: Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: Results from two transplant centres. Br J Haematol. 153:358–363. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Shanbhag S and Ambinder RF: Hodgkin lymphoma: A review and update on recent progress. CA Cancer J Clin. 68:116–132. 2018. View Article : Google Scholar : | |
|
Durkop H, Latza U, Hummel M, Eitelbach F, Seed B and Stein H: Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell. 68:421–427. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ and Inghirami G: CD30 in normal and neoplastic cells. Clin Immunol. 90:157–164. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Horie R and Watanabe T: CD30: Expression and function in health and disease. Semin Immunol. 10:457–470. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M and Diehl V: Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature. 299:65–67. 1982. View Article : Google Scholar : PubMed/NCBI | |
|
Hartmann F, Renner C, Jung W and Pfreundschuh M: Anti-CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin's disease. Leuk Lymphoma. 31:385392. View Article : Google Scholar | |
|
Falini B, Bolognesi A, Flenghi L, Tazzari PL, Broe MK, Stein H, Dürkop H, Aversa F, Corneli P, Pizzolo G, et al: Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet. 339:1195–116. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H, Schindler J, Ghetie V, Vitetta ES, Diehl V and Engert A: A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res. 8:1779–1786. 2002.PubMed/NCBI | |
|
Borchmann P, Schnell R, Fuss I, Manzke O, Davis T, Lewis LD, Behnke D, Wickenhauser C, Schiller P, Diehl V and Engert A: Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood. 100:3101–3107. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Schnell R, Dietlein M, Staak JO, Borchmann P, Schomaecker K, Fischer T, Eschner W, Hansen H, Morschhauser F, Schicha H, et al: Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol. 23:4669–4678. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, Bosly A, Pinter-Brown L, Kennedy D, Sievers EL and Gopal AK: A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 146:171–179. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, Senter PD and Alley SC: Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 16:888–897. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, et al: Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: An intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 31:684–691. 2013. View Article : Google Scholar : | |
|
Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A, La Sala A, Merli F, Stelitano C, Pozzi S, et al: ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: Results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol. 27:805–811. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yagoda A, Mukherji B, Young C, Etcubanas E, Lamonte C, Smith JR, Tan CT and Krakoff IH: Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients. Ann Intern Med. 77:861–870. 1972. View Article : Google Scholar : PubMed/NCBI | |
|
Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP and Peterson BA: Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol. 21:607–614. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW, Smith P, Qian W, Patrick P, Popova B, et al: Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol. 27:5390–5396. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, Huebner D and Ansell SM: Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: A phase 1, open-label, dose-escalation study. Lancet Oncol. 14:1348–1356. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Connors JM, Ansell SM, Fanale M, Park SI and Younes A: Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma. Blood. 130:1375–1377. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, et al: Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med. 378:331–344. 2018. View Article : Google Scholar | |
|
Straus DJ, Dlugosz-Danecka M, Alekseev S, Illes A, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, et al: Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood. 135:735–742. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Straus DJ, Długosz-Danecka M, Connors JM, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, et al: Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 8:e410–e421. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Friedberg JW, Forero-Torres A, Bordoni RE, Cline VJM, Patel Donnelly D, Flynn PJ, Olsen G, Chen R, Fon A, Wang Y, et al: Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged >/=60 years with HL. Blood. 130:2829–2837. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, et al: Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 385:1853–1862. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Viviani S, et al: Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 132:2639–2642. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, et al: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 30:2183–2189. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Huebner D, et al: Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 128:1562–1566. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kersten MJ, Driessen J, Zijlstra JM, Plattel WJ, Morschhauser F, Lugtenburg PJ, Brice P, Hutchings M, Gastinne T, Liu R, et al: Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: The phase II HOVON/LLPC Transplant BRaVE study. Haematologica. 106:1129–1137. 2021. View Article : Google Scholar : | |
|
Moskowitz AJ, Schoder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz S, Kobos R, et al: PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 16:284–292. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Garcia-Sanz R, Sureda A, de la Cruz F, Canales M, Gonzalez AP, Pinana JL, Rodriguez A, Gutierrez A, Domingo-Domenech E, Sanchez-Gonzalez B, et al: Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Ann Oncol. 30:612–620. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell SM, Crosswell HE, Islas-Ohlmayer M, Behler C, et al: Brentuximab vedotin plus bendamustine: A highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 132:40–48. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell SM, Crosswell HE, Islas-Ohlmayer M, Behler C, et al: Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. Br J Haematol. 189:e86–e90. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
O'Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, Marchi E, Turenne I, Lichtenstein R, Rojas C, et al: Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: An international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol. 19:257–266. 2018. View Article : Google Scholar | |
|
Picardi M, Della Pepa R, Giordano C, Pugliese N, Mortaruolo C, Trastulli F, Rascato MG, Cappuccio I, Raimondo M, Memoli M, et al: Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma. Blood Adv. 3:1546–1552. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Broccoli A, Argnani L, Botto B, Corradini P, Pinto A, Re A, Vitolo U, Fanti S, Stefoni V and Zinzani PL; Fondazione Italiana Linfomi ONLUS: First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: A phase 2 study of the Fondazione Italiana Linfomi. Blood Cancer J. 9:1002019. View Article : Google Scholar : PubMed/NCBI | |
|
Iannitto E, Romano A, Scalzulli PR, Bonanno V, Scalone R, Chiarenza A, Pirosa MC, Caruso AL, Minoia C, Mantuano S, et al: Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study. Eur J Haematol. 104:581–587. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Keir ME, Butte MJ, Freeman GJ and Sharpe AH: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 26:677–704. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yamamoto R, Nishikori M, Kitawaki T, Sakai T, Hishizawa M, Tashima M, Kondo T, Ohmori K, Kurata M, Hayashi T and Uchiyama T: PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood. 111:3220–3224. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, Connelly CF, Sun HH, Daadi SE, Freeman GJ, et al: PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 34:2690–2697. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, et al: Integrative analysis reveals selective 9p241 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 116:3268–3277. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, Neuberg D and Shipp MA: Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: Implications for targeted therapy. Clin Cancer Res. 18:1611–1618. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, et al: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 372:311–319. 2015. View Article : Google Scholar : | |
|
Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, et al: Nivolumab for Relapsed/Refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: Extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 36:1428–1439. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ansell S, Bröckelmann P, von Keudell G, Lee HJ, Santoro A, Zinzani PL, Collins G, Cohen J, De Boer JP, Kuruvilla J, et al: HL-398: Five-year overall survival from the CheckMate 205 study of nivolumab for relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL). Clin Lymphoma Myeloma Leuk. 21(Suppl 1): S373–S374. 2021. View Article : Google Scholar | |
|
Ramchandren R, Domingo-Domenech E, Rueda A, Trneny M, Feldman TA, Lee HJ, Provencio M, Sillaber C, Cohen JB, Savage KJ, et al: Nivolumab for Newly diagnosed Advanced-Stage classic Hodgkin lymphoma: Safety and efficacy in the phase II CheckMate 205 Study. J Clin Oncol. 37:1997–12007. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Brockelmann PJ, Goergen H, Keller U, Meissner J, Ordemann R, Halbsguth TV, Sasse S, Sökler M, Kerkhoff A, Mathas S, et al: Efficacy of Nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: The randomized phase 2 german Hodgkin study group NIVAHL Trial. JAMA Oncol. 6:872–880. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K, et al: Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 131:1183–1194. 2018. View Article : Google Scholar : | |
|
Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, et al: Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and Meta-analysis. JAMA Oncol. 5:1008–1019. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, et al: Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 35:2125–2132. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zinzani PL, Lee HJ, Armand P, Johnson N, Brice P, Radford J, Ribrag V, Molin D, Radford J, Ribrag V, et al: Three-year Follow-up of Keynote-087: Pembrolizumab monotherapy in relapsed/refractory classic Hodgkin lymphoma. Blood. 134:2402019. View Article : Google Scholar | |
|
Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, Merryman RW, Coleman KC, Dahi PB, Nieto Y, et al: PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 134:22–29. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Moskowitz AJ, Shah G, Schöder H, Ganesan N, Drill E, Hancock H, Ganesan N, Drill E, Hancock H, Davey T, et al: Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. J Clin Oncol. 39:3109–3117. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, Zhang W, Gao Y, Jin Z, Zhou J, et al: Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): A multicentre, single-arm, phase 2 trial. Lancet Haematol. 6:e12–e9. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, Xiong J, Li P, Zhao H, Huang Y, et al: Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: Results from two single-arm, phase 1 trials. Lancet Oncol. 19:1338–1350. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Mo H, Huang J, Xu J, Chen X, Wu D, Qu D, Wang X, Lan B, Wang X, Xu J, et al: Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: A dose-escalation, phase 1 study. Br J Cancer. 119:538–545. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Huang J, Xu B, Mo H, Zhang W, Chen X, Wu D, Qu D, Wang X, Lan B, Yang B, et al: Safety, activity, and biomarkers of SHR-1210, an Anti-PD-1 antibody, for patients with advanced esophageal carcinoma. Clin Cancer Res. 24:1296–1304. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Song Y, Wu J, Chen X, Lin T, Cao J, Liu Y, Zhao Y, Jin J, Huang H, Hu J, et al: A Single-arm, multicenter, phase II study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma. Clin Cancer Res. 25:7363–7369. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Nie J, Wang C, Liu Y, Yang Q, Mei Q, Dong L, Li X, Liu J, Ku W, Zhang Y, et al: Addition of low-dose decitabine to Anti-PD-1 antibody camrelizumab in relapsed/refractory classical Hodgkin lymphoma. J Clin Oncol. 37:1479–1489. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ and Ravetch JV: FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell. 28:285–295. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Song Y, Gao Q, Zhang H, Fan L, Zhou J, Zou D, Li W, Yang H, Liu T, Wang Q, et al: Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: Results of a phase 2, single-arm, multicenter study. Leukemia. 34:533–542. 2020. View Article : Google Scholar : | |
|
Song Y, Gao Q, Zhang H, Fan L, Zhou J, Zou D, Li W, Yang H, Liu T, Wang Q, et al: Tislelizumab for relapsed/refractory classical Hodgkin lymphoma: 3-year follow-up and correlative biomarker analysis. Clin Cancer Res. 28:1147–1156. 2022. View Article : Google Scholar | |
|
Boles KS, Vermi W, Facchetti F, Fuchs A, Wilson TJ, Diacovo TG, Cella M and Colonna M: A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC. Eur J Immunol. 39:695–703. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H, et al: The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 10:48–57. 2009. View Article : Google Scholar | |
|
Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, Levine Z, Beiman M, Dassa L, Achdout H, et al: The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci USA. 106:17858–17863. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Garralda E, Sanborn RE, Minchom AR, Davar D, Curigliano G, Ribrag V, Mehta A, Foss FM, Zain JM, Forero-Torres A and Ansell SM: SGNTGT-001: A phase 1 study of SEA-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies (trial in progress). J Clin Oncol. 39(15_Suppl): TPS26572021. View Article : Google Scholar | |
|
Navarro A, Diaz T, Martinez A, Gaya A, Pons A, Gel B, Codony C, Ferrer G, Martinez C, Montserrat E and Monzo M: Regulation of JAK2 by miR-135a: Prognostic impact in classic Hodgkin lymphoma. Blood. 114:2945–2951. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Meier C, Hoeller S, Bourgau C, Hirschmann P, Schwaller J, Went P, Pileri SA, Reiter A, Dirnhofer S and Tzankov A: Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod Pathol. 22:476–487. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Joos S, Granzow M, Holtgreve-Grez H, Siebert R, Harder L, Martín-Subero JI, Wolf J, Adamowicz M, Barth TF, Lichter P and Jauch A: Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. Int J Cancer. 103:489–495. 2003. View Article : Google Scholar | |
|
Van Den Neste E, André M, Gastinne T, Stamatoullas A, Haioun C, Belhabri A, Reman O, Casasnovas O, Ghesquieres H, Verhoef G, et al: A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. Haematologica. 103:840–848. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SJ, Yoon DH, Kang HJ, Hong JY, Lee HS, Oh SY, Shin HJ, Kong JH, Yi JH, Sakamoto K, et al: Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. BMC Cancer. 19:10802019. View Article : Google Scholar : PubMed/NCBI | |
|
Dutton A, Reynolds GM, Dawson CW, Young LS and Murray PG: Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol. 205:498–506. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Jundt F, Raetzel N, Muller C, Calkhoven CF, Kley K, Mathas S, Lietz A, Leutz A and Dörken B: A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa} B activity in Hodgkin and anaplastic large cell lymphomas. Blood. 106:1801–1807. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Johnston PB, Pinter-Brown LC, Warsi G, White K and Ramchandren R: Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma. Exp Hematol Oncol. 7:122018. View Article : Google Scholar : PubMed/NCBI | |
|
Gillessen S, Hüttmann A, Vucinic V, Müller H, Plütschow A, Viardot A, Topp MS, Kobe C, Böll B, Eichenauer DA, et al: Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: An experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i). Br J Haematol. 196:606–616. 2022. View Article : Google Scholar | |
|
Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B and Verma A: Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2:362009. View Article : Google Scholar : PubMed/NCBI | |
|
Bartlett JB, Dredge K and Dalgleish AG: The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 4:314–322. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Marriott JB, Muller G, Stirling D and Dalgleish AG: Immunotherapeutic and antitumour potential of thalidomide analogues. Expert Opin Biol Ther. 1:675–682. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, et al: A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. 118:5119–5125. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Boll B, Plutschow A, Burkle C, Atta J, Pfreundschuh M, Feuring-Buske M, Vogelhuber M, Sökler M, Eichenauer DA, Thielen I, et al: Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: Final results of a German Hodgkin Study Group (GHSG) phase-I trial. Br J Haematol. 185:42–52. 2019. View Article : Google Scholar | |
|
Padrnos L, Ernst B, Dueck AC, Kosiorek HE, Ginos BF, Toro A, Johnston PB, Habermann TM, Leis JF, Mikhael JR, et al: A Novel Combination of the mTORC1 inhibitor everolimus and the immunomodulatory drug lenalidomide produces durable responses in patients with heavily pretreated relapsed lymphoma. Clin Lymphoma Myeloma Leuk. 18:664–672.e2. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Marks PA and Xu WS: Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem. 107:600–708. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lane AA and Chabner BA: Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 27:5459–5468. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S, Copeland A, Buglio D, Galal A, Besterman J, et al: Mocetinostat for relapsed classical Hodgkin's lymphoma: An open-label, single-arm, phase 2 trial. Lancet Oncol. 12:1222–1228. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM, Harrison SJ, Kirschbaum M, Johnston P, Gallagher J, et al: Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: Results of a phase II study. J Clin Oncol. 30:2197–2203. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kirschbaum MH, Goldman BH, Zain JM, Cook JR, Rimsza LM, Forman SJ and Fisher RI: A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leuk Lymphoma. 53:259–262. 2012. View Article : Google Scholar | |
|
Herrera AF, Chen L, Popplewell LL, Budde LE, Mei M, Armenian SH, Darrah J, Nikolaenko L, Chen RW, Peters L, et al: Preliminary results from a phase I trial of pembrolizumab plus vorinostat in patients with relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and Hodgkin lymphoma. Blood. 134:7592019. View Article : Google Scholar | |
|
Buglio D, Mamidipudi V, Khaskhely NM, Brady H, Heise C, Besterman J, Martell RE, MacBeth K and Younes A: The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism. Br J Haematol. 151:387–396. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lemoine M, Derenzini E, Buglio D, Medeiros LJ, Davis RE, Zhang J, Ji Y and Younes A: The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood. 119:4017–4025. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Georgakis GV, Yazbeck VY, Li Y and Younes A: The histone deacetylase inhibitor vorinostat (SAHA) induces apoptosis and cell cycle arrest in Hodgkin lymphoma (HL) cell lines by altering several survival signaling pathways and synergizes with doxorubicin, gemcitabine and bortezomib. Blood. 108:22602006. View Article : Google Scholar | |
|
Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, et al: Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma. 59:863–870. 2018. View Article : Google Scholar | |
|
Maly JJ, Christian BA, Zhu X, Wei L, Sexton JL, Jaglowski SM, Devine SM, Fehniger TA, Wagner-Johnston ND, Phelps MA, et al: A Phase I/II Trial of panobinostat in combination with lenalidomide in patients with relapsed or refractory Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 17:347–353. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hamadani M, Collins GP, Samaniego F, Spira AI, Davies A, Radford J, Caimi P, Menne T, Boni J, Cruz H, et al: Phase 1 study of Adct-301 (Camidanlumab Tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory classical Hodgkin lymphoma. Blood. 132(Suppl 1): S9282018. View Article : Google Scholar | |
|
Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, Dietlein M, Kuhnert G, Kessler J, Buerkle C, et al: A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 125:4024–4031. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bartlett NL, Chen RW, Domingo-Domenech E, Forero-Torres A, Garcia-Sanz R, Armand P, Devata S, Rodriguez Izquierdo A, Lossos IS, Reeder CB, et al: A Phase 1b study investigating the combination of the tetravalent bispecific NK cell engager AFM13 and pembrolizumab in patients with relapsed/refractory Hodgkin lymphoma after brentuximab vedotin failure: Updated safety and efficacy data. Blood. 132:16202018. View Article : Google Scholar | |
|
Kochenderfer JN and Rosenberg SA: Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 10:267–2676. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Sadelain M, Brentjens R and Riviere I: The basic principles of chimeric antigen receptor design. Cancer Discov. 3:388–3898. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Johnson LA and June CH: Driving gene-engineered T cell immunotherapy of cancer. Cell Res. 27:38–58. 2017. View Article : Google Scholar : | |
|
Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH, Li X, Zhang YJ, Zhang WY, Chen MX, et al: Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: An open-label phase I trial. Clin Cancer Res. 23:1156–1166. 2017. View Article : Google Scholar | |
|
Zanotti R, Trolese A, Ambrosetti A, Nadali G, Visco C, Ricetti MM, Benedetti F and Pizzolo G: Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma. Ann Oncol. 13:1908–1914. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, Bilgi M, Wu MF, Liu H, Grilley B, et al: Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 127:3462–3471. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang D, Zeng C, Xu B, Xu JH, Wang J, Jiang LJ, Wang QX, Li CR, Wang N, Huang L, et al: Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients. Blood Cancer J. 10:82020. View Article : Google Scholar | |
|
Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, et al: Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 38:3794–3804. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jones RJ, Gocke CD, Kasamon YL, Miller CB, Perkins B, Barber JP, Vala MS, Gerber JM, Gellert LL, Siedner M, et al: Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood. 113:5920–5926. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, et al: Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2:112–1120. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I, Suhoski MM, Melenhorst JJ, Loudon B, Mato AR, et al: Nonviral RNA chimeric antigen receptormodified T cells in patients with Hodgkin lymphoma. Blood. 132:1022–1026. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Nademanee A, O'Donnell MR, Snyder DS, Schmidt GM, Parker PM, Stein AS, Smith EP, Molina A, Stepan DE, Somlo G, et al: High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors. Blood. 85:1381–1390. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Burroughs LM, O'Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ, Jones RJ, Ambinder RF, Maris MB, Blume KG, et al: Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 14:1279–1287. 2008. View Article : Google Scholar : PubMed/NCBI |
